Coherus BioSciences has sold a little under 2.5 million shares to partner Junshi Biosciences, giving the firm additional capital following a large debt financing last year.
Coherus BioSciences, Inc. has received a fresh $50m investment after completing the sale of a little under 2.5 million shares of newly-issued stock to Junshi Biosciences, the Chinese biotech that earlier this year partnered to drastically reshape Coherus’ biosimilar-orientated strategy.
Junshi has acquired 2,491,988 Coherus shares for US$20.06 per share, a 42% premium to the California-based player’s closing share price...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
